As suggested by computer modelling, deep brain stimulation delivering sporadic pulses packs as much therapeutic punch as a steady rhythm, reducing need for battery replacement surgery.
Alzforum reviews the major newsmakers of the past 12 months.
A few attempts at Alzheimer’s therapy claim hints of promise in early clinical trials, though several did not include placebo controls.
Diurnal variations disappear as less Aβ42 reaches cerebrospinal fluid. Findings may improve timing of daily amyloid treatments.
Parkinsonian symptoms in welders exposed to manganese-laden fumes worsen with continued exposure.
Methods that trawl body fluids for amyloidogenic proteins are getting more sensitive and specific, and scientists are expanding the repertoire of oligomers they can detect.
At CTAD, tau-PET data from people in different stages of various neurodegenerative diseases highlighted both commonalities and peculiarities.
Biogen and Genentech rolled out more data from their Phase 1b trials, renewing hope that amyloid removal will work and shoring up dosing for Phase 3.
Sanofi Genzyme will test a compound currently in development for Gaucher’s disease in Parkinson’s patients who carry a glucocerebrosidase (GBA) mutation.
Cognitively normal people who harbor plaques in their brains are more likely to report feelings of isolation.
Scientists at SfN presented innovative ways to slow amyloid accumulation and preserve synapses.
The tau aggregation inhibitor LMTM tanks in second Phase 3 trial for Alzheimer’s. The sponsor now plans to develop the “placebo.”
CTAD: Solanezumab Seen to Nudge AD Ever so Slightly Tau Inhibitor Fails Again—Subgroup Analysis Irks Clinicians at CTAD Much ‘Adu’ About a Little: Phase 1 Data Feeds the Buzz at CTAD Tau-PET in Down’s: Unique Patterns Among Alzheimer’s Types and Stages ...
Patients on solanezumab saw small improvements on multiple secondary endpoints.
Researchers at SfN 2016 reported that oligomeric and exosomal forms in plasma predict AD as early as a decade prior to symptoms.
No filters selected